Systematic Review Article

Clinical efficacy of ayurveda treatment modalities in the management of garbhashosh (intrauterine growth restriction): a systematic review

Sarika T. Shinde*

INTRODUCTION

In Ayurveda text, garbhashosh is also stated as vatabhinnam garbha in term, it can be defined as underdevelopment or under nourishment of part or whole body of the foetus in utero.1 Ayurveda is one of the oldest scientific medical systems in the world. The disease named as garbhashosh has been described in classical texts. Ayurveda has its roots deep seated in samhitas especially charakasamhita. This science of longevity has mentioned detailed description of almost all commonly occurring diseases. While describing specific management of garbhashosh, Sushruta suggested use of kshirbasti and medhyanna.2

“Garbhashosho cha vatanaam kshiram paramucchhate” - Ka. Khi. Bhojankalpadhyay.3

Acharya kashyapa has described garbhashosh in khilastana, 22nd chapter, while describing vatadosha karma.3 Acharya charaka while describing garbhashosh like nagodar, upavishakta, leengarba, in sharirastana

Department of Kaumarbhritya, Gaud Brahmni Ayurvedic College and Hospital, Brahanwas, Haryana, India

Received: 18 September 2020
Revised: 21 October 2020
Accepted: 26 October 2020

*Correspondence:
Dr. Sarika T. Shinde,
E-mail: drsarika843@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Concept of fetal well-being has gained importance in conventional science in recent era, but this concept of ‘supraja janana’ was a prime concern of Ayurveda since old era. Apart from prematurity, intrauterine growth restriction (IUGR) is a major public health problem in most of the developing countries. While going through ayurved classics it is revealed that garbhashosh is one of the disease, which is comparable to intrauterine growth restriction in modern medicine. In Ayurveda various drugs and preparations have been described for treatment of garbhashosh. These drugs are comparatively safe without any unwanted side effects. Aim of this work was to review and meta-analyze the effectiveness of various ayurvedic treatment modalities for garbhashosh with respect to (w.r.t.) IUGR. An attempt to expand the concept of IUGR according to Ayurveda and to yield a flourishing result to this world-wide problem through Ayurveda, this topic has been selected for the study. Going through pathology and main clinical signs and symptoms, garbhashosh can be correlated with IUGR. It is observed that, total 5 clinical studies and 1 case study have been reported on management of IUGR by using classical formulations of Ayurveda. The results and observations obtained through demographical data, effect of therapy observed on the ultrasound parameters as well clinical parameters of garbhashosh w.r.t. IUGR were statistically significant. Results were obtained in favour of most of the ayurvedic formulations. Through this review it can be stated that bruhaniya gana sidha kshirbasti and kshirpan, shatavari kshirbasti, shatavaryadi kshirbasti, yashtimadhu vidari siddha kshirbasti, shatavari ashwagandha phalaghruta kshirbasti, can be given to a pregnant women with IUGR after completion of 28th weeks of gestation, without any complication either in mother or in child. It is cost effective as compared to modern drug.

Keywords: Garbhshosh, Garbhakshaya, Intrauterine growth restriction, Kshirbasti, Kshirpan

INTRODUCTION

In Ayurveda text, garbhashosh is also stated as vatabhinnam garbha in term, it can be defined as underdevelopment or under nourishment of part or whole body of the foetus in utero.1 Ayurveda is one of the oldest scientific medical systems in the world. The disease named as garbhashosh has been described in classical texts. Ayurveda has its roots deep seated in samhitas especially charakasamhita. This science of longevity has mentioned detailed description of almost all commonly occurring diseases. While describing specific management of garbhashosh, Sushruta suggested use of kshirbasti and medhyanna.2

“Garbhashosho cha vatanaam kshiram paramucchhate” - Ka. Khi. Bhojankalpadhyay.3

Acharya kashyapa has described garbhashosh in khilastana, 22nd chapter, while describing vatadosha karma.3 Acharya charaka while describing garbhashosh like nagodar, upavishakta, leengarba, in sharirastana
chapter number 8th named as Jatisutriyaadhyaya explained garbhashosh, its etiopathology and treatment. Sushrutacharya while describing garbhadosh and its management entitleed the disease garbhashosh, in the chapter number 10th ‘garbhvinayakaran sharir’ of sharirstan. Ashtong Sangrahakar vriddha vyaghbata described different aspects of garbhashosh in sharirstan 2nd chapter ‘garbhavyapadam sharir’. Ashtong Hridyaya has mentioned the garbhashosh in sharirstan chapter number 1st ‘garbhavakrantisharir’ while describing etiopathology of garbhavyapada. In ancient text of ayurveda acharya sushruta in sharirsthan described rupa of garbhashosh as ‘matu kukshi na purayati’ it means size of abdomen not increases accordingly to the gestational age of mother. Fetus inside uterus remains small for dates. Another important rupa of garbhashosh is ‘manda spandana’.

Dalhana in his comentry stated that there is absence of ‘ojā’ in garbha. Acharya Kashyapa described same symptoms. Acharya Charaka in sharirstnsa described a different symptom, of a women having garbhashoshha, is she delivers the little one after a year, after attaining proper growth of fetus in utero. Acharya Vagbhata also opines that the garbha remains for year in the uterus.

Intrauterine growth restriction (IUGR) is defined as babies with birth weight below the tenth percentile for a given gestational age for a given population as a result of pathological restriction in their ability to grow.

**Aim**

This study aims at thorough review of published data of kshirbasti with different Ayurveda interventions in the management of IUGR, published from 2010 to 2020 that to explore Ayurveda approach towards IUGR and efficacy of available Ayurveda treatment modalities specifically kshirbasti and kshirpan on the foetal growth and development.

**METHODS**

**Research question**

In modern medicine treatment of garhashosh (IUGR) is empirically directed towards weight gain of mother and foetus by rest, oxygen (O₂) therapy, gluco-corticosteroids, nutrition with high protein diet, hydration, mechanical therapy like vibrations, pharmacological therapy- low dose aspirin, hyper alimentation, in the form of trans amniotic, intragastric and intravenous routes. It is very clear from foresaid facts that treatment is cost effective, time consuming and with drastic side effects of drugs and steroids on pregnant mother.

All these facts highlighted that mother suffering form garbhashosh-IUGR, has to face lot of problems. Per se growth retardation in fetus does not cause any harm to mother. Unfortunately for a women with a growth retarded infant, risk of having another is twofold! That’s why people of present era are looking forward for Ayurveda treatment modalities. So there is need of strong evidences of safe and effective treatment.

Hence in an attempt to expand the concept of IUGR according to Ayurveda and to yield a flourishing results on IUGR by qualitative analysis of previously published findings of Ayurveda treatment modalities specifically kshirbasti and kshirpan to generate evidence on its safety and efficacy.

**Data sources**

The data sources consist of quality literature search.

Electronic databases like PubMed, scopus, DHARA portal, AYUSH Research portal, Ayurveda research data base by MS Baghel, Goggle scholar and manual search in libraries

Records identified through other sources include preferred reporting items for systematic reviews and meta-analyses (PRISMA).

Journals, publications, postgraduate thesis and dissertations.

**Criteria of selection**

The relevant research works through different data sources, the result of which were processed, are selected according to the classification criteria.

**Year of publication**


**Language**

Research work published only in English language were included.

**Number of citations of the article**

Articles with greater number of citation were given preference.

**Study design**

This review included randomized controlled trials (RCTs), controlled clinical trials (CCTs), case reports and case series. Evidence-based studies were given preference and systematic review was done using PRISMA guidelines.

**Key words**

Research publications with keywords like kshirbasti, kshirpan, IUGR, garbhashosh, garbhakshay and oligohydramnios were considered for review.
**Types of publications**

Original research articles were taken for study.

**DATA COLLECTION**

Details of number of studies identified, screened and assessed for eligibility for inclusion of qualitative synthesis is given in PRISMA flow chart.

The records screened indicates the number of studies that remained after the exclusion of duplicates and studies rejected after reading the abstracts. The number of articles eliminated on the basis of the examination of their reviews.

On the other hand, 6 articles for which the full text is available are assessed in the next step and their final number is given under full-text articles assessed for qualitative and quantitative evaluation of study.

<table>
<thead>
<tr>
<th>Research work obtained through databases</th>
<th>Searching research work obtained through other sources</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n=21)</td>
<td>(n=4)</td>
</tr>
<tr>
<td>Total clinical research work screened (n=16)</td>
<td>Research work excluded duplicates (n=9)</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Research work assessed for eligibility (n=16)</td>
<td></td>
</tr>
<tr>
<td>Research work excluded with reasons—subject of interest, only abstracts available and others reasons (n=11)</td>
<td></td>
</tr>
<tr>
<td>Final full research articles selected for qualitative evaluation of study (n=6)</td>
<td></td>
</tr>
<tr>
<td>Research articles selected for quantitative evaluation of study</td>
<td>(n=6)</td>
</tr>
</tbody>
</table>

**RESULTS**

<table>
<thead>
<tr>
<th>Sl. no.</th>
<th>Author</th>
<th>Journal</th>
<th>YOP</th>
<th>Study type</th>
<th>Methodology</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Dewaik-ar and Shinde</td>
<td>2014</td>
<td>Control-led clinical trial</td>
<td>Total 60 patients of garbhashosh (asym IUGR) having their written consent were selected and divided into two groups. One group called trial–30 patients, in which bruhaniya gana sidha kshirbasti and kshirpan was given, while in another group called control group-30 patients to whom injection alamine SN and capsule alamine forte therapy was given.</td>
<td>It is observed that in both trial and control group, maternal fundal height, abdominal girth and fetal abdominal circumference, amniotic fluid, fetal weight, ponderal index showed highly significant improvement (p&lt;0.001). Upashaya was seen in 25 patients (83.33%) of trial group and 21 patient of control group (70%). Brimhaniya gana sidha kshirabasti and kshirpana can be given in IUGR condition to improve the growth parameters without any complication.</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Kour J et al</td>
<td>2016</td>
<td>A case study</td>
<td>A 23 year old primi gravida with 34 weeks of gestation USG report showing A.F.I. &lt;4 shatavari ksheer basti 500 ml was administered through rectal route.</td>
<td>Shatavari kshirabasti is very effective treatment modality to increase the amniotic fluid and for good nourishment of foetus.</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Suprabha K et al</td>
<td>2017</td>
<td>A case series study</td>
<td>In this case series, total 3 pregnant patients completing their 7th months of pregnancy, with the complaint of intrauterine growth</td>
<td>It was observed that after the basti treatment, there was increase in the fetal movements, liquor and</td>
<td></td>
</tr>
</tbody>
</table>

Continued.
<table>
<thead>
<tr>
<th>Sl. no.</th>
<th>Author</th>
<th>Journal YOP</th>
<th>Study type</th>
<th>Methodology</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>Singh S</td>
<td>2017</td>
<td>Clinical trial</td>
<td>Group A consisted of 30 pregnant subjects were treated with a combination of following medicines: dhatrilaauha 250 mg BD orally with water, yashyimadhu, vidari siddha ksheerabasti 60 ml, calcium 500 mg 1 OD orally, folic acid 5 mg 1 OD orally. Group B consisted of 30 pregnant subjects were treated with a combination of following medicines: yashyimadhu, vidari siddha ksheerabasti 60 ml, iron supplement 100 mg ferrous ascorbate 1 OD orally, calcium 500 mg 1 OD orally, and folic acid 5 mg 1 OD orally. Group C consisted of 30 pregnant subjects were treated as control group, they were regularly taking following medicines since 4th month of pregnancy: iron supplement 100 mg ferrous ascorbate 1 OD orally, calcium 500 mg 1 OD orally, folic acid 5 mg 1 OD orally. Evaluation of the efficacy of treatments was based upon the assessment of improvements in signs and symptoms. This analysis shows that, the USG measurements of fetuses gain in AC, FL, HC was significantly more in group A and group B mothers. There is significant difference in baby weight at birth. Group-A and group-B baby weights at birth significantly more than group-C. Amongst the three treatment modalities, a combination of yashtimadhu, vidari siddha basti with dhatrilaauha is the best treatment modality during pregnancy for maintenance of good health of both baby and the mother.</td>
<td>restriction, reduced fetal movement and oligohydraminos were administered with shatavaryadi ksheerapaka basti 450 ml once daily in the morning, for consecutive 10 days. also fetal weight. In addition, there was also increase in maternal weight and improvement in fatigue, body ache, etc. From the study it has been observed that, in conditions of garbha kshaya (IUGR), administration of shatavaryadi ksheerapaka basti is beneficial in terms of fetal growth and maternal wellbeing.</td>
</tr>
<tr>
<td>5</td>
<td>Anu MS et al</td>
<td>2018</td>
<td>A case report</td>
<td>A 28 year old married woman second gravida with 33 week of gestation given her consent admitted for premature uterine contaction, isoxxsuprine hydrochloride injection 5 mg IM 6 hourly (total 4 doses), half tablet of tidilan retard (isoxxsuprine 40 mg) 1st, 2nd and 3rd day; betamethasone 1 ampule IM 2 doses (12 hours apart) 4th day. Shatavaryadi ksheerapaka basti 450 ml was administered through rectal route 5th 6th day shatavaryadi ksheerapaka 90 ml orally twice daily empty stomach for a week. Shatavaryadi ksheerapaka basti is found to be very efficient in preventing premature contractions.</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Jadhav AS</td>
<td>2017</td>
<td>A case report</td>
<td>A 23 year old female, primi gravida at 31 weeks of gestation with moderate oligohydroamnios; 1st day=matra basti til taila - 60 ml, 2nd,7th day=ksheerbasti 100 ml 7 days, 8th day=matra basti til taila - 60 ml, 9th,15th day=ksheerbasti 100 ml 7 days, 16th day=matra basti til taila - 60 ml (shatavary, ashwagandha, phalaghrutasidhha ksheer basti) Shatavari, ashwagandha, phalaghruta sidhha ksheer basti has proven very effective modality to increase amniotic fluid and good nourishment of fetus in this case.</td>
<td></td>
</tr>
</tbody>
</table>
DISCUSSION

In this systematic review, out of these six research works, two research articles explained effectiveness of kshirbasti on IUGR, one research work showed effectiveness of kshirbasti on premature uterine contractions, two research works were carried out to find out effectiveness of kshirbasti on oligohydramnios and one research work was carried out to find efficacy of kshirbasti in IUGR and oligohydramnios as well. Among these six research studies included, four studies mainly on only kshirbasti, two research studies on kshirpan and kshirbasti both.\(^9,14\)

**Efficacy of kshirbasti**

The aim of this work to review systematically the effectiveness of ‘bruhaniya gana saddha kshirbasti and kshirpan’ ‘shatavari kshirbasti’ ‘yashtimadhuvidari siddha kshirbasti’ ‘shatavaryadi ksheerapaka basti’ in the patients with IUGR, oligohydramnios, premature uterine contractions showed highly effective results in increasing the maternal weight gain, fundal height, abdominal girth,\(^9,10,12,13\) Increase in fetal biometry, amniotic fluid index, baby birth weight. Definite need of alternative, safe and effective treatment option through Ayurveda might be quite helpful. Management of premature uterine contractions through shatavaryadi kshirbasti formulation might be useful for further studies in this era.

Bhruniya gana saddha kshirbasti and kshirpan drugs formulation having dominance of snigdha, sheeta, guru guna, sheeta virya, madhur ras, madhur vipak, pruthvi-aap mahabhutadhihya, vata shaman and anuloman, bhruniya, garbhavuddhikar properties.\(^9\) Combination of kshirpan and kshirbasti given more beneficial results. Treatment modality helped in proper rasadhatu nirmiti, rasaraktadhatu prasadan results in prakrut garbhaposhkansh nirmiti and garbhavridhhi in IUGR.

Drugs in shatavaryadi kshirpaki basti endowed with bruhan, balya, pushhitdayak, shonitraprasadan, vatanuloman properties which help in formation of new tissues and rejuvenating the already formed dhatus.\(^11\) Shatavaryadi basti consist of shatavari, bala and arjuna, which acting as dhatu vardhak increases the rasa dhatu and in turn increases the amniotic fluid. Dhatu vardhana by constructive metabolism and thus have a definite action on fetel growth related disorders.

Drugs formulation in yashtimadhu, vidari saddha kshirbasti having predominance of madhur rasra, which is indicated in garbhini paricharya.\(^12\) Ksheer used for basti is much needed during pregnancy as it is having rasayana, vrishya, balya, jivaniya, stanyakara, shramhara properties. Medicated kshir introduced by anal route having more systemic and local effects like great absorptive capacity and vatanuloman. This therapy helped in fulfilling the dietary demands as well as it is preventing the common discomforts observed during pregnancy. In turn helping in normal, healthy, and timely growth of the foetus.

Formulation consist of shatavari, bala, arjuna in shatavaryadi ksheerapaka for basti and ksheerapan preparation drugs posesess antioxytocic, antistress, hypotensive, cardio-tonic and vasodilating properties which might be effectively curtailed the progress of premature contractions.\(^13\) Per rectal basti administration of shatavaryadi kshirpaka for two consecutive days was effective in preventing the uterine contractions and further advancement to preterm labour. Antioxytocic effect of shatavari was proved through many studies as it produce a specific block of pitocin induced contractions, through this research its action as uterine sedative was confirmed.

In shatavari ashwagandhha phalaghrita kshirabasti, Shatavari having jivaniya bruhiya, garbhapradha properties, it also acts as bruhiya and tarpak for jala mahabhuata which helped in improvement of amniotic fluid.\(^14\) Ashwagandhha posseses bruhiya, rasayana, deepniya, vrushya and garbhshapaka properties which acted by providing good nutrition. Phalaghrita acts as balya to uterus, its snigdha guna helps in improvement of garbhadhak.

**Safety of kshirbasti**

According to World Health Organization (WHO) the definition of drug is any substance or product that is used or is intended to modify or explore physiological systems or pathological state for the benefit of recipient. This review yielded and flourished lights on safety of kshirbasti treatment modality in treating a disease condition like IUGR, oligohydramnios without any untoward harm to garbhn. Vagbhatacharya had mentioned the characteristics of an ideal drug as a drug, which is having properties of bahukalpa, bahu guna rich in all its characteristics. Through this review study it is been observed that selection of drugs in all kshirbasti formulations were from authentic references, having kapha vataghna, bhruniya and garbhavridhikar properties. Administration was in the correct dose and standard methods of preparation and administration were followed. No severe adverse events were observed in all trials. These case studies focusing to use kshirpaki basti, hoping that these drugs will be more effective in counteracting IUGR with its anabolic properties without any side effects. This will be a great contribution to Ayurveda obstetrician in the management of IUGR.

**CONCLUSION**

This was a required effort to form the ladder towards basti chikitsa in garbhini, which was not frequently practiced before. Ksheerbasti can be given in a pregnant woman after completion of 28th weeks of gestation. Cost is effective as compared to modern drug and it is safe with no adverse effects. Kshirbasti pratayagam kala was observed in more than 4-6 hours. It can be given in larger quantity i.e. observed is more than 400 ml for effective action and quick absorption through anal route. Kshirbasti as sukha prasadavakara and improving garbhadhahran kala and
liquor increasing effect of basti was observed. Uterine premature contractions can be effectively managed through ksheerbasti.

**Funding:** No funding sources

**Conflict of interest:** None declared

**Ethical approval:** Not required

**REFERENCES**


**Cite this article as:** Shinde ST. Clinical efficacy of Ayurveda treatment modalities in the management of garbhashosh (IUGR): a systematic review. Int J Adv Med 2020;7:1878-83.